Results 171 to 180 of about 161,532 (251)

A RNase H2-Linked TaqMan-MGB Quantitative Real-Time PCR Assay for Differential Detection of <i>Mycoplasma hyopneumoniae</i> Live-Attenuated Vaccine Strains. [PDF]

Transbound Emerg Dis
Peng K, Wei Y, Wu Y, Yuan T, Li J, Jiang P, Xie Q, Feng Z.   +7 more
europepmc   +1 more source

Purification and concentration of model viruses using single‐pass tangential flow filtration

Biotechnology Progress, EarlyView.
Single‐pass TFF was developed for an enveloped and non‐enveloped virus for use in continuous downstream purification processes. Enveloped virus was concentrated and purified. Abstract The vaccine and viral vector industry is growing at an accelerated rate.
Luis Alberto Mejía‐Manzano, Lynn Manchester, Grace Wallis, Kan Wang, Bruce P. Lee, Michael Betenbaugh, Caryn L. Heldt   +6 more
wiley   +1 more source

Nano-adjuvants enhance the immunogenicity and safety of infectious bursal disease virus vaccines: a comprehensive review. [PDF]

Front Immunol
Asif TA, Ji P, Qiao X, Yang Q, Jiang D, Zhang G.   +5 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Advances and Translational Challenges in <i>Toxoplasma gondii</i> Vaccine Development: From Antigen Discovery to mRNA and One Health Strategies. [PDF]

Vet Sci
Qadeer A, Tharwat M, Khan MZ, Juhasz A, Alshanbari FA.   +4 more
europepmc   +1 more source

Viscosity of concentrated mRNA solutions: Implications for downstream processing

Biotechnology Progress, EarlyView.
Abstract Messenger RNA (mRNA) therapeutics can be used to protect against infectious disease and for the treatment of cancers and genetic disorders. In order to obtain the desired therapeutic dosage, it is necessary to concentrate the mRNA to levels where the viscosity of the mRNA solutions can become significant.
Amin Javidanbardan, Fatemeh Najafi, Ziqiao Wang, Andrew L. Zydney   +3 more
wiley   +1 more source

Vaccine-derived T-cell responses are insufficient to generate protective immunity to SARS-CoV-2. [PDF]

Sci Rep
Cha SC, Szymura SJ, Anderson A, Dong Z, Kandel A, Oh E, Palmer M, Arango K, Zhang J, Kwak LW.   +9 more
europepmc   +1 more source

Screening of bispecific antibodies during single cell cloning of recombinant Chinese hamster ovary cell lines to improve titer and product quality

Biotechnology Progress, EarlyView.
Abstract Development of therapeutic bispecific antibodies (BsAbs) poses significant manufacturability challenges associated with correct chain pairing and an increased diversity of impurities. Here we address this with a product quality assessment during cell line development (CLD), forgoing the need for genetic characterization during cell line ...
Molly Robinson, Jessica Willmott, Holly Corrigall, Daniela Lega, Joseph Stirling, Vithiya Vimalraj, Mitul Patel, Robyn Emmins   +7 more
wiley   +1 more source

Comparative Evaluation of Polymeric Nanocarriers for DNA Vaccine Delivery Against <i>Avian Orthoavulavirus 1</i> in Chickens. [PDF]

Viruses
Khattab AH, Bayoumi M, Eldin ZE, Ahmed BM, Amer HM.   +4 more
europepmc   +1 more source

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

Biotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing, Tomoki Igi, Daniel Strauss   +2 more
wiley   +1 more source